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Abstract
Background: The availability of up-to-date, executable, evidence-based medical knowledge is
essential for many clinical applications, such as pharmacovigilance, but executable knowledge is
costly to obtain and update. Automated acquisition of environmental and phenotypic associations in
biomedical and clinical documents using text mining has showed some success. The usefulness of
the association knowledge is limited, however, due to the fact that the specific relationships
between clinical entities remain unknown. In particular, some associations are indirect relations
due to interdependencies among the data.
Results: In this work, we develop methods using mutual information (MI) and its property, the
data processing inequality (DPI), to help characterize associations that were generated based on
use of natural language processing to encode clinical information in narrative patient records
followed by statistical methods. Evaluation based on a random sample consisting of two drugs and
two diseases indicates an overall precision of 81%.
Conclusion: This preliminary study demonstrates that the proposed method is effective for
helping to characterize phenotypic and environmental associations obtained from clinical reports.
Background
The availability of up-to-date, executable, evidence-based
medical knowledge is essential for clinical applications
such as quality of care, decision support, clinical informa-
tion needs and hypothesis generation. Traditional work in
the field has focused on constructing and maintaining
knowledge bases manually using expert medical resources,
but it is costly and time-consuming to establish evidence-
based knowledge [1,2]. Additionally, because medical
knowledge constantly changes, updating the knowledge is
also problematic. It is, therefore, beneficial to develop
automated methods to help create evidence-based knowl-
edge and to help keep it up to date.
It is well known that much of evidence-based knowledge
in biomedicine is buried in medical literature, reference
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Open Accesswebsites and books, and narrative clinical reports [3-5].
In this work, we focus on narrative clinical reports.
Generating associations, such as drug side effects,
disease-drug therapies, and disease-symptom associa-
tions, based on phenotypic and environmental informa-
tion in patient records provides knowledge concerned
w i t ht h ep r a c t i c eo fm e d i c i n ea n dt h ed i s e a s ep r o c e s s ,
and acquisition of this knowledge has become possible
with advances in natural language processing and data
mining. Several lines of investigations have studied
automated methods for creating and updating knowl-
edge bases from narrative reports of patient records
[6-9]. Those studies demonstrated that automated
methods involving natural language processing (NLP)
and statistics can generate meaningful associations
between clinical phenotypes and drugs with great
efficiency. Although these associations are useful, they
have limitations because the specific relationships are
not known but are critical. In particular, some associa-
tions are indirectly related. For example as shown in
Figure 1a, using association statistics based on informa-
tion in the patient record, we found that a symptom
shortness of breath (SOB) was associated with a disorder
hypertensive disease (HD). SOB was also found to be
associated with a drug Metolazone (ML), and ML was
found to be associated with HD. However, the statistical
method was not able to determine whether the symptom
SOB was directly associated with the drug ML and
therefore caused by it or treated by it, or the symptom
SOB was just indirectly associated with ML because it
was the manifestation of the disease HD that it treats,
and therefore was a confounding event. Characterizing
the associations as ‘direct’ or ‘indirect’ would be an
important feature for a medical knowledge base to have
but resolving these confounding interdependencies is
complicated.
Statistical adjustments have been widely used in many
epidemiological studies in order to infer confounding
effects of variables [10,11]. For example, people who
d r i n km o r ec o f f e em a ya l s os m o k em o r ec i g a r e t t e sa n d
drinkmorealcohol. Determiningwhethercoffeedrinking
by itself increases mortality risk, and is not just a marker
for some other causal factor can be approached using
statistical methods [12]. The basic methods are to include
measures of potential confounders as covariates in a
regression model, or to stratify the data on these
confounders. These methods are often called “statistically
controlled” or “adjusted” for potential confounders.
While statistically adjusted methods provide a rich
means of inferring confounding effects of variables,
they still cannot characterize the associations or differ-
entiate between those that are direct or indirect. Further
research would be desirable to develop sophisticated
models for this purpose.
Mutual information (MI), a measure of the degree of
statistical dependence between two variables, has been
introduced in biomedicine for numerous applications
ranging from epidemiological data to biological data
[13]. The simplest way to use MI is to test for a
significant association between two variables. Here the
null hypothesis is that the two variables are indepen-
dent. The distribution of the MI under the null
hypothesis is (with appropriate scaling) that of a chi-
square variable, leading to a significance test for the
presence of the association [13]. Cox used MI redun-
dancy to detect a causal nonlinear relation between fast
food consumption and risk of campylobacteriosis in
w o m e n[ 1 4 ] .A sam e a s u r eo fd e g r e eo ft e m p e r a t u r e
dependence in sex determination, MI has been used to
yield insights into evolutionary, environmental and
ecological changes [15].
In the bioinformatics field, MI has also been applied to
genomics data. Butte and Kohane developed algorithms
that reconstruct networks based on MI. The authors
inferred that edges exist between gene pairs which have
an MI above a certain threshold [16]. More recently, MI
and its properties have been applied to eliminate indirect
regulatory factors in genome-wide networks. Margolin
e ta la p p l i e dM Ia n dt h ed a t ap r o c e s s i n gi n e q u a l i t y( D P I )
Figure 1
Schematic diagram of the effect of DPI. (a) and (c):
Among two paths between ML and SOB (ML-SOB, ML-HD-
SOB), ML-SOB was eliminated by applying DPI (shown as 1
in table 1). (b) and (d): Similarly, among two paths between
HF and SOB (HF-SOB, HF-HD-SOB), HF-HD-SOB was
eliminated by applying DPI (shown as 6 in table 1).
(e) Combining evidence from (c) and (d), the path between
ML-SOB would more likely to be ML-HD-HF-SOB. ML:
Metolazone; HD: Hypertensive Disease; HF: Hear Failure;
SOB: Shortness of Breath.
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work, DPI was used to determine that there was no direct
path between gene1 and gene3 based on the fact that the
MI between gene1 and gene3 was less than the MI
between gene1 and gene2,a n da l s ot h eM Ib e t w e e ng e n e 2
and gene3 [18].
In this paper we extend our previous work [8,9,19],
which establishes associations between clinical entities,
and propose an information theoretic approach similar
to those described above, which uses MI and DPI to help
differentiate between direct and indirect associations,
thereby improving our understanding of them.
Results
Data statistics
There were 25,074 discharge summaries from New
York-Presbyterian Hospital (NYPH) in 2004. After data
selection and filtering, there were 1,997 unique drug
concepts, 732 unique symptom concepts and 947
unique disease concepts in the database.
Qualitative evaluation
There were 53 pairs that were found to be associated
with the two drugs (Metolazone and Rosiglitazone) and
two diseases (heart disease and diabetes). Among them,
27 pairs were randomly selected for qualitative evalua-
tion, which included 14 symptoms associated with the
two drugs and 13 symptoms associated with the two
diseases. The overall precision was 0.81, where the
precision was 0.86 and 0.77 for drug-symptom pairs and
disease-symptom pairs, respectively. A subset of the
results of the evaluation is shown in Table 1, and the full
evaluation set is provided in the supplementary files
(Full Drug-Symptom evaluation set available from
http://www.dbmi.columbia.edu/~xiw7002/MI/rx-sx.doc;
Full Disease-Symptom evaluation set available from
http://www.dbmi.columbia.edu/~xiw7002/MI/dx-sx.
doc).
Discussion
Characterizing clinically important associations based
on statistical methods that utilize clinical information
extracted from narrative clinical reports is challenging
because the associations could correspond to several
different relationships. For example, based on clinical
knowledge, a drug-symptom association may represent
the following relations: 1) a ‘treat’ relation where the
drug is used to treat the symptom (i.e. Ibuprofen-
headache); 2) a ‘cause’ relation where the drug causes
the symptom (i.e. Rosiglitazone-headache); or 3) an
‘indirect’ relation where the drug treats a disease which
is manifested by the symptom (i.e. Rosiglitazone-polyuria).
Similarly, a disease-symptom association may represent:
1) a ‘direct manifestation’ where the symptom is a
manifestation of the disease (i.e. diabetes-polyuria), 2) an
‘indirect manifestation’ where the symptom is a mani-
festation of another disease which is a frequent
comorbidity of the disease in the association (i.e.
diabetes-angina pectoris), or 3) a ‘treatment-induced’
relation where the symptom is caused by a medication
or other treatment procedures (i.e. diabetes-chills). By
Table 1: Results of evaluation
# Association of interest
MI ((95%CI)
Mediators for association of interest
MI (95%CI)
Result
*(D/I/E)
RS**
RX-SX RX-DX DX-SX
1 Metolazone-Shortness of
Breath
0.086(0.075–0.097)
Metolazone-Hypertensive Disease
0.526(0.495–0.557)
Hypertensive Disease-Shortness of Breath
0.132(0.113–0.152)
II
2 Metolazone-Headache
0.070(0.059–0.083)
Metolazone-Hypertensive Disease
0.526(0.495–0.557)
Hypertensive Disease-Headache
0.084(0.072–0.095)
EE
3 Metolazone-constipation
0.034 (0.023–0.046)
Metolazone-Hypertensive Disease
0.526(0.495–0.557)
Hypertensive Disease-constipation 0.019
(0.009–0.028)
ED
4 Rosiglitazone-Headache
0.079 (0.068–0.091)
Rosiglitazone-Diabetes
0.443(0.327–0.513)
Diabetes-Headache
0.117(0.093–0.128)
ID
5 Rosiglitazone-Chest Pain
0.077(0.069–0.088)
Rosiglitazone-Diabetes
0.443(0.327–0.513)
Diabetes-Chest Pain
0.090(0.074–0.115)
EE
DX1 -S X D X 1 -D X 2 DX2 -S X
6 Hypertensive Disease-
Shortness of Breath 0.132
(0.113–0.152)
Hypertensive Disease-Heart Failure
0.651(0.563–0.738)
Heart Failure-Shortness of Breath
0.173(0.158–0.186)
II
7 Diabetes-Chest Pain
0.131(0.115–0.148)
Diabetes-Heart Failure
0.435(0.317–0.543)
Heart Failure-Chest Pain
0.184(0.169–0.193)
II
DX: Disease; RX: Drug; SX: Symptom; *I: Indirect association; D; Direct association; E: Either association; **RS: Reference Standard.
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relations between particular types of entities along with
MI and DPI, our findings demonstrated the potential of
the approach for differentiating between direct and
indirect associations because it achieved a precision of
81%. More interestingly, combining evidence obtained
from the approach benefited our understanding of the
environmental and phenotypic information in clinical
settings. For example, in Figure 1, two sets of evidence
were combined to help characterize the association
between Metolazone and SOB by joining graphs 1c)
and 1d) to generate 1e). In c), the path between
Metolazone and SOB was eliminated as was the path
between HD and SOB in d). Therefore, a possible path
between Metolazone and SOB could be meditated
through HD and heart failure.
Upon examination of our results, it appeared that the
strengths of the drug-disease/symptom associations can
be used to help infer the actual type of relationship.
When reviewing the associations and their strengths, we
noted that the strong drug-disease/symptom associations
were mainly ‘treat’ relations whereas the weaker drug-
disease/symptom associations were either ADEs or ‘treat’
relations for drugs with broad indications. This observa-
tion makes sense clinically and would be interesting to
study further using a larger dataset.
Although our results showed that the information
theoretic approach could improve our understanding
of the associations generated from automated methods,
it is, however, still a challenge to accurately identify the
nature of associations from patient records, and espe-
cially to infer causal links between drug and diseases/
symptoms. First, an ‘indirect’ link based on the DPI
method only implies that a ‘direct’ link has not been
proven from the data we have. Therefore, the smallest MI
in a triangle does not necessarily imply that there is no
direct link. All applications of MI and DPI in character-
izing the interdependencies among entities should be
understood in this context. Second, determining the
correct temporal sequence for environmental and phe-
notypic events would be helpful in removing confound-
ing relations. Temporally, an ADE must follow the
medication event, and a drug treatment event must
follow the diagnosis event or symptom event. For
example, incorrect ‘cause’ relations between a drug and
a symptom would be eliminated if it were known that
the symptom preceded the drug administration. In this
paper, we restricted our research to discharge summaries
documenting a single hospital stay and to ADEs
occurring during that time. We assumed that symptoms
associated with a drug could be ADEs of the drug or
manifestations of diseases/symptoms the drug treats.
Similarly, we assumed that symptoms associated with a
disease could be manifestations of that disease or
manifestations of diseases highly associated with that
disease. Including contextual filters consisting of the
sections where the clinical information appears, as
described in more detail in the Method section, was
important. For drug-disease/symptom associations, pre-
liminary studies showed that a simple strategy without
the contextual filters failed to find many ADEs,
particularly rare ones. This was likely because symptoms
induced by drugs appeared to be highly diluted by those
associated with the diseases the drugs treated since the
‘treat’ relations occurred much more frequently. Our
strategy for estimating the temporal sequences was very
naïve. We will explore development of more sophisti-
cated temporal models and use of a more comprehensive
longitudinal record including outpatient visits and
pharmacy orders.
There are a number of other factors affecting precision.
One factor is that some symptoms may have been
correctly characterized by our method as ‘ADEs’ but were
considered wrong in our evaluation because they have
not been discovered yet. Another factor is that another
association within the DPI triangle could also be indirect
thereby confounding our analysis and demonstrating
that our method requires more complexity. For example,
our method incorrectly determined that the association
between Rosiglitazone and headache was indirect because
it considered the MIs between Rosiglitazone and diabetes,
and diabetes and headache. However the latter association
is also indirect. Based on clinical knowledge we know
that diabetes is highly associated with hypertension
which includes the manifestation headache. This, how-
ever, is not due to a limitation of the method presented
in this paper because adjusting all possible confounders
in an analysis is beyond the scope of the current study,
and is challenging for statistical and information
theoretic methods in general. Another problem is due
to an information gap that exists in patient records
because patient records are fragmented and clinicians
may document certain events and ignore others.
Our study had a few limitations. First, the study was
restricted to discharge summaries of inpatients only. As a
result, our findings should be understood in the context
of a sick patient population. However, the same method
could be used with outpatient reports, which would
include a more balanced population. A second limita-
tion of this investigation is that the evaluation was
performed on only 37 associations involving only two
drugs and two diseases. A third limitation is that one of
the co-authors (XW) generated the reference standard
using the reference resources. A more comprehensive
evaluation involving a larger sample size and more
curators will be undertaken in future work.
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The availability of up-to-date, executable, evidence-based
medical knowledge is essential in biomedicine for many
applications. Automatic methods, which are aimed at
acquiring knowledge from clinical sources, such as clinical
reports, have shown promise for constructing and updating
practice-based knowledge. In this study, we applied an
information theoretic approach involving MI and DPI to
improve our understanding of associations consisting of
environmental and phenotypic entities occurring in the
EHR that were obtained using NLP and statistical methods.
The results achieved by the methodology demonstrate its
usefulness for generating executable medical knowledge,
which can be used in important clinical applications, such
as pharmacovigilance.
Methods
Materials
The data warehouse in NYPH collects and maintains a
variety of structured and unstructured data for patient
records. Textual discharge summaries dictated in the year
2004 were de-identified and used in this study after
obtaining IRB approval.
Method framework
The framework for detecting environmental and pheno-
typic associations based on information in narrative
reports primarily involves two major phases: acquiring
associations and characterizing association, as shown in
Figures 2A and 2B.
Acquiring associations
There are three steps involved in acquiring associations,
which have been described in more detail in [20]. That
work aimed to capture adverse drug events occurring
during the hospital stay where both the adverse event
and the drug therapy were mentioned in the discharge
summary. The steps consist of (a) processing the reports
using NLP to encode clinical entities; (b) selecting coded
entities corresponding to certain environmental and
phenotypic properties, and then filtering them to reduce
the amount of potentially confounding information,
such as negation and eliminating certain sections; (c)
applying statistical methods to reveal associations
between environmental and phenotypic pairs. The
method is briefly described below.
a) Process the EHR
MedLEE (the Medical Language Extraction and Encoding
System) was used to parse and transform discharge
summaries into structured representations consisting of
UMLS codes with modifiers. For example, a sentence ‘the
patient has a headache’ is encoded as UMLS code
C0018681 corresponding to headache,w h i c hh a sa
certainty modifier high certainty corresponding to has.
b) Select and filter the data
The semantic classes of the UMLS codes were used to
select the appropriate information types for this study,
which consisted of two types of phenotypic entities
(disease and symptom) and one environmental entity
type (drug). For example, the UMLS codes that corre-
sponded to the UMLS semantic classes Disease or
Syndrome [T047], Mental or Behavioral Dysfunction
[T048], and Neoplastic Process [T191], were used for
disease entities. For example, heart failure would be
selected because it is classified in the UMLS as semantic
class T047. The selected phenotypes and drugs were then
filtered to exclude entities with specific modifier values,
such as family history, certainty modifiers signifying low
or no, and status modifiers signifying past events. Two
additional contextual filters consisting of the sections
where the clinical information occurred were also
applied as a very rough estimation of the appropriate
temporal ordering of drug-disease/symptom and dis-
ease-symptom events. Heuristically, we know that a
s y m p t o mo c c u r r i n gd u r i n gah o s p i t a ls t a yc o u l d :1 )b e
an ‘adverse drug event (ADE)’ induced by a drug, 2) be a
symptom that is an indication for the use of a drug, or 3)
be associated with a drug given for a disease or another
symptom the drug ‘treats’.I no r d e rt oc a p t u r eA D E s ,w e
should only consider symptoms that follow the admin-
istration of a drug; if a drug is given after the symptom
occurs, that drug is unlikely to be the cause of the
symptom and more likely to be a treatment. Therefore,
drugs mentioned in sections other than Hospital Course
and Medications were filtered out in an effort to
eliminate medications not given in the hospital, such
Figure 2
Schematic diagram of methodological framework.
A: Acquiring Associations; B: Characterizing Associations;
EHR: Electric Health Records; MI: Mutual Information;
DPI: Data Processing Inequality; Dx: disease; Rx: drug;
Sx: symptom.
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section were included because typically these contain
medications prescribed in outpatient visits prior to
admission and continued in the hospital stay, or
medications started at admission and continued unless
otherwise specified. The second contextual filter filtered
out symptoms mentioned in certain sections signifying
that they occurred before the hospital stay, such as Chief
Complaint and History of Present illness (HPI) since
they more frequently describe the disease a patient has
than an ADE.
c) Determine association tables
We obtained counts for statistical analysis consisting of
pairs of co-occurring disease-disease, drug-disease/symp-
t o ma n dd i s e a s e - s y m p t o ma sw e l la sc o u n t so fr e l e v a n t
types of events. A pair was considered to co-occur if each
entity of the pair was selected and not filtered out, and
occurred within a single discharge summary. To test the
hypothesis of no association between a pair of entities,
the c
2 statistic was used. A description of how the cutoff
point was determined is described by Cao and colleagues
[19,21]. A list was then generated consisting of associa-
tions above the cutoff and their strengths.
Characterizing associations
The task of characterizing associations between entities
as direct or indirect follows four major steps: (a)
selecting associations of interest, (b) determining the
mediators for associations of interest (c), calculating MI
for all associated pairs that are involved, and (d)
applying DPI to characterize an association of interest
as ‘direct’, ‘indirect’ or ‘either’.
a) Select associations of interest
In this study, we focused on two types of associations:
disease-symptom (Dx-Sx) associations and drug-symp-
tom (Rx-Sx) associations.
b) Determine mediators for associations of interest
For a drug-symptom association, a mediator was chosen,
which was a disease Dx associated with the symptom
where the disease had the strongest statistical association
with the drug. This was done because the disease was
likely to be the treatment indication for the drug, as
explained in the Discussion. Thus, the MIs of the two
other relevant types of associated pairs (drug-Dx, Dx-
symptom) were calculated because they potentially
could be indirect paths for the drug-symptom associa-
t i o n ,a ss h o w ni nF i g u r e s1 aa n d1 c .S i m i l a r l y ,f o ra
disease1-symptom pair, a mediator disease2was chosen,
which was associated with the symptom and which had
the strongest statistical association with disease1.M I sf o r
pairs of disease1-disease2 and the disease2-symptom
were calculated for similar reasons, as shown in Figures
1b and 1d.
c). Calculate Mutual Information (MI)
We calculated the MI following the method proposed by
Cover [22]. Given two random variables X and Y within
a joint probability mass function p(x, y) and marginal
probability mass function p(x) and p(y), the mutual
information MI(X; Y) is the relative entropy between
joint distribution and the product distribution p(x)p(y),
i.e.,
MI x y p x y
pxy
pxpy
(;) (,) l o g [
(,)
()()
] = ∑ ∑
Confidence intervals of MI were calculated by boot-
strapping to estimate the variability of the MIs.
d) Apply the Data Processing Inequality (DPI)
The DPI states that if random variables X, Y and Z form a
Markov chain X–>Y–>Z, then the mutual information
between X and Y is greater than or equal to the mutual
information between X and Z. That is MI(X; Y) >= MI(X; Z)
[17,22,23]. We then used the DPI to characterize the
associations for the selected pairs. For example, as
illustrated in Figure 1, if a drug Metolazone (ML) and a
symptom shortness of breath (SOB) are associated via a
disease (i.e., hypertensive disease(HD)), and MI(ML,
SOB) <= min [MI(ML, HD); MI(HD, SOB)] and the 95%
CIs do not overlap, then we classified the association of
the drug-symptom as ‘indirect’;i ft h e9 5 %C I sb e t w e e n
the two paths overlapped, the association was classified
as‘either’,andifneitherofthoseconditionsweremet,the
association was classified as ‘direct’.
Evaluation
We evaluated our methods using a random set of
symptoms associated with two drugs of interest, Rosigli-
tazone and Metolazone, and another random set of
symptoms associated with two diseases of interest,
hypertensive disease and diabetes.
Reference standard
Side effects of the two drugs as specified by Micromedex
were considered to be ‘direct’ associations for drug-
symptom pairs, while manifestations of the two diseases
of interest as specified by WebMD were considered
‘direct’ associations for disease-symptom pairs [24,25].
In contrast, manifestations of diseases, which the drugs
treat, as specified by MicroMedex, were considered to be
“indirect” associations for drug-symptom pairs. Simi-
larly, manifestations of other diseases highly associated
with either of the two diseases of interest as specified by
WebMD were considered as “indirect” associations for
disease-symptom pairs. If any of the pairs were
BMC Bioinformatics 2009, 10(Suppl 9):S13 http://www.biomedcentral.com/1471-2105/10/S9/S13
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classified as being ‘either’. The reference standard was
generated by combining all the ‘direct’, ‘indirect’ and
‘either’ associations for the drugs and diseases.
Quantitative evaluation
All the selected associations of the two drugs and two
diseases were compared to the reference standard.
Precision was used to assess the classification perfor-
mance of our method. In this study precision was
measured as the ratio of the number of distinct pairs
returned by our method that match the pairs in the
reference standard, divided by the total number of pairs
found by the method.
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